Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis

in European Journal of Endocrinology
View More View Less
  • 1 Department of Endocrinology, Leeds Centre for Diabetes and Endocrinology, St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • | 2 Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), Faculty of Medicine and Health, University of Leeds, Leeds, UK
  • | 3 Department of Medical Oncology, Leeds Cancer Centre, St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Correspondence should be addressed to R D Murray; Email: robertmurray@nhs.net
Restricted access

Context

The use of the CTLA4 inhibitor, ipilimumab, has proven efficacious in the treatment of melanoma, renal carcinoma and non-small cell lung cancer; however, it is associated with frequent immune-related adverse events (irAE). Ipilimumab-induced hypophysitis (IIH) is a well-recognised and not infrequent endocrine irAE.

Objective

To investigate the timing of onset and severity of adrenal and thyroid hormone dysfunction around the development of IIH in patients treated for melanoma.

Design

Aretrospective review of hormone levels in consecutive adult patients treated with ipilimumab (3 mg/kg) for advanced melanoma as monotherapy or in combination with a PD-1 inhibitor.

Results

Of 189 patients, 24 (13%; 13 males; 60.5 ± 12.2 years) presented with IIH at a median of 16.1 (range: 6.7–160) weeks after commencing treatment, occurring in 14 (58%) after the fourth infusion. At the presentation of IIH, corticotroph deficiency was characterised by an acute and severe decrease in cortisol levels to ≤83 nmol/L (≤3 μg/dL) in all patients, often only days after a previously recorded normal cortisol level. Free thyroxine (fT4) levels were observed to decline from 12 weeks prior to the onset of cortisol insufficiency, with the recovery of thyroid hormone levels by 12 weeks after the presentation of IIH. A median fall in fT4 level of 20% was observed at a median of 3 weeks (IQR: 1.5–6 weeks) prior to the diagnosis of IIH.

Conclusion

IIH is characterised by an acute severe decline in cortisol levels to ≤83 nmol/L at presentation. A fall in fT4 can herald the development of ACTH deficiency and can be a valuable early indicator of IIH.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1366 1366 1104
Full Text Views 179 179 161
PDF Downloads 72 72 46
  • 1

    Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM & Ernstoff MS et al.Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology 1999 17 27452751. (https://doi.org/10.1200/JCO.1999.17.9.2745)

    • Search Google Scholar
    • Export Citation
  • 2

    Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993 72 30913098. (https://doi.org/10.1002/1097-0142(19931115)72:10<3091::aid-cncr2820721034>3.0.co;2-v)

    • Search Google Scholar
    • Export Citation
  • 3

    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J & Dummer R et al.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019 381 15351546. (https://doi.org/10.1056/NEJMoa1910836)

    • Search Google Scholar
    • Export Citation
  • 4

    Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Sileni V, Schachter J, Garbe C & Bondarenko I et al.Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine 2019 381 626636. (https://doi.org/10.1056/NEJMoa1904059)

    • Search Google Scholar
    • Export Citation
  • 5

    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D & Hassel JC et al.Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 363 711723. (https://doi.org/10.1056/NEJMoa1003466)

    • Search Google Scholar
    • Export Citation
  • 6

    Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller Jr WH & Lao CD et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet: Oncology 2015 16 375384. (https://doi.org/10.1016/S1470-2045(1570076-8)

    • Search Google Scholar
    • Export Citation
  • 7

    Wolchok JD, Rollin L, Larkin J. Nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2017 377 25032504. (https://doi.org/10.1056/NEJMc1714339)

    • Search Google Scholar
    • Export Citation
  • 8

    Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacology 2017 8 49. (https://doi.org/10.3389/fphar.2017.00049)

    • Search Google Scholar
    • Export Citation
  • 9

    Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine 2015 13 211. (https://doi.org/10.1186/s12916-015-0455-8)

    • Search Google Scholar
    • Export Citation
  • 10

    Prodam F, Caputo M, Mele C, Marzullo P, Aimaretti G. Insights into non-classic and emerging causes of hypopituitarism. Nature Reviews: Endocrinology 2021 17 114129. (https://doi.org/10.1038/s41574-020-00437-2)

    • Search Google Scholar
    • Export Citation
  • 11

    Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, Taverna G, Cosottini M, Lupi I. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. American Journal of Pathology 2016 186 32253235. (https://doi.org/10.1016/j.ajpath.2016.08.020)

    • Search Google Scholar
    • Export Citation
  • 12

    Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine 2014 6 230ra45. (https://doi.org/10.1126/scitranslmed.3008002)

    • Search Google Scholar
    • Export Citation
  • 13

    Siddiqui MS, Lai ZM, Spain L, Greener V, Turajlic S, Larkin J, Morganstein DL. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. Journal of Endocrinological Investigation 2021 44 195203. (https://doi.org/10.1007/s40618-020-01297-3)

    • Search Google Scholar
    • Export Citation
  • 14

    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG & Ding S et al.Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology 2009 27 61996206. (https://doi.org/10.1200/JCO.2009.23.4799)

    • Search Google Scholar
    • Export Citation
  • 15

    Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM & McArthur GA et al.Melanoma staging: evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians 2017 67 472492. (https://doi.org/10.3322/caac.21409)

    • Search Google Scholar
    • Export Citation
  • 16

    Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology and Metabolism 2014 99 40784085. (https://doi.org/10.1210/jc.2014-2306)

    • Search Google Scholar
    • Export Citation
  • 17

    Faje A Hypophysitis: evaluation and management. Clinical Diabetes and Endocrinology 2016 2 15. (https://doi.org/10.1186/s40842-016-0034-8)

  • 18

    de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Hormone and Metabolic Research 2019 51 145156. (https://doi.org/10.1055/a-0843-3366)

    • Search Google Scholar
    • Export Citation
  • 19

    Albarel F, Gaudy C, Castinetti F, Carré T, Morange I, Conte-Devolx B, Grob JJ, Brue T. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology 2015 172 195204. (https://doi.org/10.1530/EJE-14-0845)

    • Search Google Scholar
    • Export Citation
  • 20

    Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clinical Cancer Research 2015 21 749755. (https://doi.org/10.1158/1078-0432.CCR-14-2353)

    • Search Google Scholar
    • Export Citation
  • 21

    Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 2014 21 371381. (https://doi.org/10.1530/ERC-13-0499)

    • Search Google Scholar
    • Export Citation
  • 22

    Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Yéléhé-Okouma M, Weryha G, Klein M, Gillet P. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database. Scientific Reports 2019 9 19419. (https://doi.org/10.1038/s41598-019-56026-5)

    • Search Google Scholar
    • Export Citation
  • 23

    Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncology 2018 4 173182. (https://doi.org/10.1001/jamaoncol.2017.3064).

    • Search Google Scholar
    • Export Citation
  • 24

    Nogueira E, Newsom-Davis T, Morganstein DL. Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Therapeutic Advances in Endocrinology and Metabolism 2019 10 2042018819896182. (https://doi.org/10.1177/2042018819896182)

    • Search Google Scholar
    • Export Citation
  • 25

    De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Long GV, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 2018 21 274282. (https://doi.org/10.1007/s11102-018-0866-6)

    • Search Google Scholar
    • Export Citation
  • 26

    Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European Journal of Endocrinology 2019 181 211219. (https://doi.org/10.1530/EJE-19-0238)

    • Search Google Scholar
    • Export Citation
  • 27

    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA & Richards JM et al.Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet: Oncology 2015 16 522530. (https://doi.org/10.1016/S1470-2045(1570122-1)

    • Search Google Scholar
    • Export Citation
  • 28

    Albarel F, Castinetti F, Brue T. MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. European Journal of Endocrinology 2019 181 R107R118. (https://doi.org/10.1530/EJE-19-0169)

    • Search Google Scholar
    • Export Citation
  • 29

    Snyders T, Chakos D, Swami U, Latour E, Chen Y, Fleseriu M, Milhem M, Zakharia Y, Zahr R. Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary 2019 22 488496. (https://doi.org/10.1007/s11102-019-00978-4)

    • Search Google Scholar
    • Export Citation
  • 30

    Alzenaidi AA, Dendy J, Rejjal L. Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma. Journal of the Louisiana State Medical Society 2017 169 49.

    • Search Google Scholar
    • Export Citation
  • 31

    Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 2019 104 54995506. (https://doi.org/10.1210/jc.2019-00423)

    • Search Google Scholar
    • Export Citation
  • 32

    Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocrine Practice 2012 18 351355. (https://doi.org/10.4158/EP11273.OR)

    • Search Google Scholar
    • Export Citation
  • 33

    Faje A Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016 19 8292. (https://doi.org/10.1007/s11102-015-0671-4)

    • Search Google Scholar
    • Export Citation
  • 34

    Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. European Journal of Endocrinology 2012 167 15. (https://doi.org/10.1530/EJE-12-0167)

    • Search Google Scholar
    • Export Citation